Hallucinations oseltamivir

The FDA has received 103 reports, occurring between August 29, 2005, and July 6,2006, of delirium, hallucinations, and self-injury in pediatric patients (mostly from Japan) following treatment with oseltamivir. 

Oseltamivir and zanamivir are neuraminidase inhibitors that have activity against both influenza A and influenza B viruses. When administered within 48 hours of the onset of illness, oseltamivir and zanamivir may reduce the duration of illness by approximately 1 day versus placebo. Oseltamivir is approved for treatment in those older than the age of 1 year, while zanamivir is approved for treatment in those older than the age of 7 years. The recommended dosages vary by agent and age (see Table 41-3), and the recommended duration of treatment for both agents is 5 days. The FDA has received 103 reports, occurring between August 29,2005, and July 6,2006, of delirium, hallucinations, and self-injury in pediatric patients (mostly from Japan) following treatment with oseltamivir. 

Psychiatric A 43-year-old man who had taken high-dose oseltamivir 150 mg bd for 2 days for HlNl influenza A became disoriented in time and place and had visual hallucinations although neurotoxicity due to oseltamivir... 

Psychiatric There is some controversy about the potential of oseltamivir to cause adverse neuropsychiatric effects, since concerns were raised about the risk of hallucinations, delirium, and abnormal activity [253, 254 ]. Even deaths have been reported [255. ... 

---